MedTrace Logo

Paclitaxel in Treating Patients With Ovarian Stromal Cancer

NCT00006227 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2020-03-05

Study results available
· View outcomes & findings →

Summary

This phase II trial studies the effectiveness of paclitaxel in treating patients who have ovarian stromal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Conditions

  • Adult Type Ovarian Granulosa Cell Tumor
  • Ovarian Gynandroblastoma
  • Ovarian Sertoli-Leydig Cell Tumor
  • Ovarian Sex Cord Tumor With Annular Tubules
  • Ovarian Steroid Cell Tumor

Interventions

DRUG

Paclitaxel

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Gynecologic Oncology Group

    lead NETWORK

Principal Investigators

  • Linda Van Le · NRG Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-11-20
Primary Completion
2016-07-16
Completion
2016-07-16

Countries

  • United States
  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006227 on ClinicalTrials.gov